PMID- 29115881
OWN - NLM
STAT- MEDLINE
DCOM- 20180125
LR  - 20181202
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 18
IP  - 17
DP  - 2017 Dec
TI  - A review of current and developing fixed-dose LABA/LAMA combinations for treating 
      COPD.
PG  - 1833-1843
LID - 10.1080/14656566.2017.1403583 [doi]
AB  - The current GOLD (Global Initiative for Chronic Obstructive Lung Disease) 
      recommendations suggest using long acting beta2 agonists (LABA) and long acting 
      muscarinic antagonists (LAMA) in combination for group B COPD patients with 
      persistent symptoms, group C COPD patients with further exacerbations on LAMA 
      therapy alone and for group D COPD patients with or without combination with 
      inhaled corticosteroids (ICS). Thus, there is a lot of interest in developing 
      LABA/LAMA combinations for maintenance therapy of chronic stable COPD. Areas 
      covered: Many LABA/LAMA combinations have successfully been approved through 
      carefully designed pivotal clinical trials. The current clinical use of LABA/LAMA 
      combinations in COPD will continue to evolve as new trials with and without 
      inhaled corticosteroids are completed. Expert opinion: Combining different 
      classes of bronchodilators in a single inhaler is an attractive concept that can 
      potentially improve patient adherence to therapy. Because LABA/LAMA combinations 
      are the preferred treatment option for preventing COPD exacerbations in the 
      updated GOLD guidelines for COPD, they will be clinically used. Future treatment 
      of COPD should revolve around a personalized approach based on characterization 
      of the COPD phenotype.
FAU - Lal, Chitra
AU  - Lal C
AD  - a Pulmonary, Critical Care, Allergy and Sleep Medicine , Medical University of 
      South Carolina , Charleston , SC , USA.
FAU - Strange, Charlie
AU  - Strange C
AD  - a Pulmonary, Critical Care, Allergy and Sleep Medicine , Medical University of 
      South Carolina , Charleston , SC , USA.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Review
DEP - 20171115
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Adrenergic beta-2 Receptor Agonists)
RN  - 0 (Muscarinic Antagonists)
SB  - IM
MH  - Administration, Inhalation
MH  - Adrenergic beta-2 Receptor Agonists/pharmacology/*therapeutic use
MH  - Humans
MH  - Muscarinic Antagonists/pharmacology/*therapeutic use
MH  - Pulmonary Disease, Chronic Obstructive/*drug therapy
OTO - NOTNLM
OT  - Chronic obstructive pulmonary disease
OT  - Global Initiative for Chronic Obstructive Lung Disease
OT  - bronchodilators
OT  - long acting muscarinic antagonists
OT  - long acting beta2 agonists
EDAT- 2017/11/09 06:00
MHDA- 2018/01/26 06:00
CRDT- 2017/11/09 06:00
PHST- 2017/11/09 06:00 [pubmed]
PHST- 2018/01/26 06:00 [medline]
PHST- 2017/11/09 06:00 [entrez]
AID - 10.1080/14656566.2017.1403583 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2017 Dec;18(17):1833-1843. doi: 
      10.1080/14656566.2017.1403583. Epub 2017 Nov 15.